The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease
Open accessAbstract
UNLABELLED: Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand ((68)Ga-pentixafor) for diagnostic receptor targeting, (177)Lu- and (90)Y-pentixather were recently developed as endoradiotherapeutic vectors. Here, we summarize the first-in-human experience in 3 heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma undergoing CXCR4-directed endoradiotherapy. METHODS: CXCR4 target expression was demonstrated by baseline (68)Ga-pentixafor PET. Each treatment was approved by the clinical ethics committee. Pretherapeutic (177)Lu-pentixather dosimetry was performed before (177)Lu-pentixather or (90)Y-pentixather treatment. Subsequently, patients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow rescue. RESULTS: A remarkable therapeutic effect was visualized in 2 patients, who showed a significant reduction in (18)F-FDG uptake. CONCLUSION: CXCR4-targeted radiotherapy with pentixather appears to be a promising novel treatment option in combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for patients with advanced multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., de Vries, E. G. E., & Walenkamp, A. M. E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 635
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Self-citationCXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
Burger, J. A., & Peled, A. (2009) · Leukemia · doi:10.1038/leu.2008.299 · Cited by 462
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Self-citationEmerging targets in cancer management: role of the CXCL12/CXCR4 axis
Dubrovska, A., Cojoc, M., Peitzsch, Trautmann, F., Polishchuk, & Telegeev (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36109 · Cited by 254
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong, M., Breeman, W. A. P., Valkema, R., Bernard, B. F., & Krenning, E. P. (2005) · PubMed · Cited by 244
PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent
Gourni, E., Demmer, O., Schottelius, M., D'Alessandria, C., Schulz, S., Dijkgraaf, I., Schumacher, U., Schwaiger, M., Kessler, H., & Wester, H.-J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098798 · Cited by 228
Self-citationPhilipp‐Abbrederis, K., Herrmann, K., Knop, S., Schottelius, M., Eiber, M., Lückerath, K., Pietschmann, E., Habringer, S., Gerngroß, C., Franke, K., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404698 · Cited by 221
Self-citationPET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand
Demmer, O., Gourni, E., Schumacher, U., Kessler, H., & Wester, H. (2011) · ChemMedChem · doi:10.1002/cmdc.201100320 · Cited by 198
Self-citationDisclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
Wester, H. J., Keller, U., Schottelius, M., Beer, A., Philipp-Abbrederis, K., Hoffmann, F., Šimeček, J., Gerngross, C., Lassmann, M., Herrmann, K., et al. (2015) · Theranostics · doi:10.7150/thno.11251 · Cited by 198
Self-citationThe impact of intra-clonal heterogeneity on the treatment of multiple myeloma
Brioli, A., Melchor, L., Cavo, M., & Morgan, G. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.12805 · Cited by 130
The Genetic Architecture of Multiple Myeloma
Prideaux, S. M., O’Brien, E. C., & Chevassut, T. J. T. (2014) · Advances in Hematology · doi:10.1155/2014/864058 · Cited by 125
Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
Peled, A., & Tavor, S. (2013) · Theranostics · doi:10.7150/thno.5150 · Cited by 108
Romer, A., Seiler, D., Marincek, N., Brunner, P., Koller, M., Ng, Q. K. T., Maëcke, H. R., Müller‐Brand, J., Rochlitz, C. F., Briel, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2559-8 · Cited by 78
Molecularly Targeted Therapies in Multiple Myeloma
de la Puente, P., Muz, B., Azab, F., Luderer, M. J., & Azab, A. K. (2014) · Leukemia Research and Treatment · doi:10.1155/2014/976567 · Cited by 69
Ratajczak, M. Z., Serwin, K., & Schneider, G. (2013) · Theranostics · doi:10.7150/thno.4621 · Cited by 49
Minimal Residual Disease in Multiple Myeloma
Munshi, N. C., & Anderson, K. C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2124 · Cited by 45
Tamas, K. R., Domańska, U., van Dijk, T. H., Timmer‐Bosscha, H., Havenga, K., Karrenbeld, A., Sluiter, W. J., Beukema, J. C., van Vugt, M. A. T. M., de Vries, E. G. E., et al. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150105155615 · Cited by 18
Cited by
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengass, J., Engelhardt, M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 544
Self-citationRadiotheranostics: a roadmap for future development
Herrmann, K., Schwaiger, M., Lewis, J. S., Solomon, S. B., McNeil, B. J., Baumann, M., Gambhir, S. S., Hricak, H., & Weissleder, R. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30821-6 · Cited by 327
Self-citationRadiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 284
Korbecki, J., Kojder, K., Kapczuk, P., Kupnicka, P., Gawrońska-Szklarz, B., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020843 · Cited by 273
Radiotheranostics in oncology: Making precision medicine possible
Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131
Metadata
- Authors
- Herrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., Keller, U., Schirbel, A., Samnick, S., Lassmann, M., Kropf, S., Buck, A. K., Einsele, H., Wester, H.-J., & Knop, S.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2015-11-12
- Volume
- 57
- Issue
- 2
- Pages
- 248-251
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2339037925
- Cited by
- 276
- References
- 20
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.